Floatz logo

Capecitabine

Microsatellite Stable

Federation Francophone de Cancerologie DigestiveSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

18 Active assets in the Microsatellite Stable cohort.

Asset / SponsorPhaseRating
Irinotecan
M.D. Anderson Cancer Center
Phase 2BB
Eloxatin
M.D. Anderson Cancer Center
Phase 2BB
Pembrolizumab
NextCure, Inc.
Phase 2B
Epirubicin
NextCure, Inc.
Phase 2B
(+)-VINCRISTINE
M.D. Anderson Cancer Center
Phase 2B

View all 18 →

Same molecule, other indications

Capecitabine is also rated in:

Locally Advanced Rectal CancerDormant
BBB
Indicative ·
75 / 100
View asset →
colorectal neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →
rectal carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →